Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.